ArticleTheranostics2018
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 72 citations in OpenAlex.
- AI-guided design of plectin-1-targetedJournal of nanobiotechnology · 2026Article
- Plectin 1d Isoform as a Potential Regulator of Metastatic Progression in Papillary Thyroid Carcinoma.International journal of molecular sciences · 2026Article
- Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI.International journal of molecular sciences · 2025Article
- Imaging Cell Surface Plectin in PDAC Patients - A First-In-Human Phase 0 Study Report.Molecular imaging and biology · 2025Article
- Plectin, a novel regulator in migration, invasion and adhesion of ovarian cancer.Cell & bioscience · 2025Article
- Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective.Pharmaceutics · 2024Review
- Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.International journal of molecular sciences · 2024Review
- Biomarkers in Ovarian Cancer: Towards Personalized Medicine.Proteomes · 2024Review
- Plectin plays a role in the migration and volume regulation of astrocytes: a potential biomarker of glioblastoma.Journal of biomedical science · 2024Article
- Role of plectin and its interacting molecules in cancer.Medical oncology (Northwood, London, England) · 2023Review
- A Bitter Taste Receptor as a Novel Molecular Target on Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.American journal of translational research · 2023Article
- The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems.Pharmaceutics · 2022Review
- [Pharmaceutics · 2022Article
- Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity.Frontiers in pharmacology · 2022Article
- Susceptibility of cytoskeletal-associated proteins for tumor progression.Cellular and molecular life sciences : CMLS · 2021Review
- A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells.Bioorganic chemistry · 2021Article
- Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review.International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
Advances in genomics and proteomics drive precision medicine by providing actionable genetic alterations and molecularly targeted therapies, respectively. While genomic analysis and medicinal chemistry have advanced patient stratification with treatments tailored to the genetic profile of a patient's tumor, proteomic targeting has the potential to enhance the therapeutic index of drugs like poly(ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitors in breast and ovarian cancer patients with BRCA1/2 mutations have shown promise. About 10% of the patients who received Olaparib (PARP inhibitor) showed adverse side effects including neutropenia, thrombocytopenia and in some cases resulted in myelodysplastic syndrome, indicating that off-target effects were substantial in these patients. Through proteomic analysis, our lab previously identified plectin, a cytolinker protein that mislocalized onto the cell surface during malignant transformation of healthy ovarian tissue. This cancer specific phenotype allowed us to image pancreatic cancer successfully using plectin targeted peptide (PTP) conjugated to nanoparticles or displayed on capsid protein of adeno-associated virus (AAV) particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.